Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]
Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? [Yahoo! Finance]
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags [Yahoo! Finance]
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.